Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.
Overview
The race for dominance in weight-loss and diabetes treatments has reached a fever pitch. Investors choosing between Eli Lilly and (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) face a difficult decision in 2026.
Eli Lilly leads with a diverse U.S. portfolio and rapid expansion into metabolic health. Novo Nordisk remains a global powerhouse in insulin and obesity care, leveraging decades of specialized expertise. Both companies are currently capitalizing on the massive demand for GLP-1 medications, making them the primary contenders in the modern healthcare landscape.
Details
Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical stocks globally, focusing on high-growth areas like oncology and immunology. It relies heavily on wholesale distributors, including McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH). Customer concentration like this adds a layer of risk to the business, as these three major partners handle a significant share of its distribution and product logistics.
Source
Originally published at www.fool.com.